Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orna Therapeutics is a preclinical-stage biotechnology company developing engineered circular RNA (oRNA) therapeutics delivered by proprietary lipid nanoparticles for in vivo CAR and gene-editing–like applications in oncology, autoimmune, infectious, and genetic diseases; lead programs (e.g., ORN-252, ORN-101) have shown robust B cell and plasma cell depletion and tumor suppression in animal and non-human primate models, with first clinical entry planned around 2026.[1][2][4][6][8]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Orn Health.